Scar & Burn

TARGET

(_Topic_Al Silicone in _Restorin_G Scars and Burn Tissue - _Evaluating _Therapy)

TARGET is a current, large-scale IRB-approved observational study on the effectiveness of topical/transdermal treatments for scar/burn characteristics, symptoms, and patient perceptions. It further evaluates the reduction of pain during the course of treatment.

Key Interim Results

·69% of patients noticed reduction in scar size, results confirmed by clinician measurements, which showed a statistically significant reduction in the percentage of patients with largest (>20cm) scars from baseline (p<.003)
Over an average 128 days of scar/burn cream treatment use, patients reduced their usage of pain medications by 69% (p<.001)
Patients also reported reductions in itching (p<.001) and scar/burn interference with general activity, mood, sleep, life enjoyment, and an improvement in emotional well-being with the use of the treatment compound (p<.05)
Patients reported no serious adverse events and that the creams were safe and well-tolerated.

Become a Study Investigator

To learn more about our TARGET study, please call our dedicated Healthcare Provider HelpDesk at

(800) 641-4857.

Principal Investigator

H. John Visser, DPM

Mid-West Podiatry and Associates
Creve Coeur, MO

Director of Residency Training in Podiatric Surgery
SSM Health DePaul Hospital
DePaul, MO

Faculty, Department of Orthopedics
Washington University School of Medicine
St. Louis, MO

AffiliationsDiplomate of the American Board of Podiatric Surgery
Diplomate of the American Board of Podiatric Medicine
Fellow of the American College of Foot and Ankle Surgeons
Past-President of the Missouri Podiatric Medical Association

Study Objective

To assess patient perceptions of topical treatment formulations for scar/burn tissue via a patient-reported survey.

Assessment Tools

TARGET evaluates Participants’ perceptions about the prescribed study medication using validated scales (the Vancouver Scar Scale, Patient and Observer Scar Assessment Scale, and Manchester Scale) and evaluates pain scores using the University of Texas MD Anderson Cancer Center’s Brief Pain Inventory (BPI).

TARGET Outcomes

Positive interim data from our TARGET study has been presented at leading international conferences, including the 7th Joint Meeting of the European Tissue Repair Society (ETRS) & the Wound Healing Society (WHS), held in Copenhagen, Denmark, among others.

Key interim results include the following:

Reductions in scar size were reported in 69% of patients, results confirmed by clinician measurements.

Patients reported reductions in itching.

Patients reported reductions in scar/burn interference with general activity, mood, sleep, life enjoyment and an improvement in emotional well-being.

Patients reduced their usage of pain medications by 69%.

A majority of patients indicated the creams helped/improved scar appearance. The scar/burn creams were safe and well-tolerated, and no serious adverse events occurred.

TARGET Conference Highlights

MORE TARGET CONFERENCES

Become a Study Investigator

To learn more about our TARGET study, please call our dedicated Healthcare Provider HelpDesk at

(800) 641-4857.